Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: An evaluation using existing data

Vaccine

Volumn 31, Issue SUPPL.3, 2013, Pages

  Picón, Teresa ^a   Alonso, Lucía ^a   García Gabarrot, Gabriela ^a   Speranza, Noelia ^a   Casas, Mariana ^a   Arrieta, Fernando ^b   Camou, Teresa ^a   Rosa, Raquel ^a   Helena De Oliveira, Lucia ^c   Verani, Jennifer Rabke ^d  

^a Ministry of Public Health Uruguay   (Uruguay)

^b Immunization Department   (Uruguay)

^c PAN AMERICAN HEALTH ORGANIZATION   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Pneumococcal infections; Pneumococcal vaccines; Streptococcus pneumoniae; Uruguay

Indexed keywords

PNEUMOCOCCUS VACCINE;

CALCULATION; CATCH UP GROWTH; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; URUGUAY;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION, SECONDARY; INFANT; LOGISTIC MODELS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PUBLIC HEALTH SURVEILLANCE; REGISTRIES; URUGUAY;

EID: 84879245046     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.059     Document Type: Review

References (32)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(September (9693)):893-902.
2. Ferrari C.A., Pirez G.M., Martinez A.A., Algorta R.G., Chamorro V.F., Guala B.M., et al. Etiology of community acquired pneumonia in inpatients children Uruguay 1998-2004. Rev Chilena Infectol 2007, 24(February (1)):40-47.
3. Hortal M., Iraola I., Camou T. Avances multidiciplinarios para el control integral de Streptococcus pneumoniae. Montevideo, Uruguay: Oficina Regional de la Organización mundial de la Salud 2004.
4. Hortal M., Estevan M., Iraola I., De Mucio B. A population-based assessment of the disease burden of consolidated pneumonia in hospitalized children under five years of age. Int J Infect Dis 2007, 11(May (3)):273-277.
5. Pírez M.C., Berrondo C., Giacometti M., DeMiguel M., Pascales I., Algorta G., et al. Neumonía bacteriana adquirida en la comunidad en niños hospitalizados. Archivos de Pediatría del Uruguay 2003, 74:6-14.
6. Ministry of Public Health (Uruguay). Situación de la enfermedad neumocócica; 2008.
7. Hortal M., Sehabiague G., Camou T., Iraola I., Estevan M., Pujadas M. Pneumococcal pneumonia in hospitalized Uruguayan children and potential prevention with different vaccine formulations. J Pediatr 2008, 152(June (6)):850-853.
8. Camou T., Palacio R., Di Fabio J.L., Hortal M. Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations. Vaccine 2003, 21(May (17/18)):2093-2096.
9. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(September (9)):810-815.
10. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003, 362(August (9381)):355-361.
11. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N., et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(October (14)):1341-1348.
12. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(March (9465)):1139-1146.
13. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(October (9546)):1495-1502.
14. Mahon B.E., Hsu K., Karumuri S., Kaplan S.L., Mason E.O., Pelton S.I., et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 2006, 24(March (14)):2514-2520.
15. Barricarte A., Castilla J., Gil-Setas A., Torroba L., Navarro-Alonso J.A., Irisarri F., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 2007, 44(June (11)):1436-1441.
16. Deceuninck G., De Wals P., Boulianne N., De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec. Can Pediatr Infect Dis J 2010, 29(June (6)):546-549.
17. Ruckinger S., van der Linden M., Reinert R.R., von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method. Vaccine 2010, 28(July (31)):5012-5016.
18. Dominguez A., Ciruela P., Garcia-Garcia J.J., Moraga F., de Sevilla M.F., Selva L., et al. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. Vaccine 2011, 29(November (48)):9020-9025.
19. Andrews N., Waight P.A., Borrow R., Ladhani S., George R.C., Slack M.P., et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One 2011, 6(12):e28435.
20. Vestrheim D.F., Lovoll O., Aaberge I.S., Caugant D.A., Hoiby E.A., Bakke H., et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008, 26(June (26)):3277-3281.
21. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(October (10)):760-768.
22. Castaneda E., Agudelo C.I., Regueira M., Corso A., Brandileone M.C., Brandao A.P., et al. Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 2009, 28(September (9)):e265-e270.
23. Ronveaux O., Arrieta F., Curto S., Laurani H., Danovaro-Holliday M.C. Assessment of the quality of immunization data produced by the national individual registration system in Uruguay, 2006. Rev Panam Salud Publica 2009, 26(August (2)):153-160.
24. Ruckinger S., Dagan R., Albers L., Schonberger K., von Kries R. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine 2011, 29(December (52)):9600-9606.
25. Goldblatt D., Southern J., Ashton L., Richmond P., Burbidge P., Tasevska J., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006, 25(April (4)):312-319.
26. Scott P., Rutjes A.W., Bermetz L., Robert N., Scott S., Lourenco T., et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011, 29(December (52)):9711-9721.
27. PAHO. Meeting T.A.G. Buenos Aires, Argentina 2011 -- Final Report, PAHO, Washington DC, 2011.
28. WHO. Pneumococcal vaccines WHO position paper - 2012 - Recommendations. Vaccine 2012 May 20.
29. Crisinel P.A., Chevalier I., Rallu F., Tapiero B., Lamarre V., Thibault R., et al. Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: a pediatric tertiary care center experience. Eur J Pediatr 2010, 169(November (11)):1311-1315.
30. Pan American Health Organization. Informe Regional de SIREVA II: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores, 2000-2005. Washington DC; 2007.
31. Pan American Health Organization. Informe Regional de SIREVA II, 2009: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores. Washington DC; 2010.
32. Pirez M.C., Algorta G., Cedres A., Sobrero H., Varela A., Giachetto G., et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo Uruguay. Pediatr Infect Dis J 2011, 30(August (8)):669-674.